A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer

This study assessed the efficacy/safety of rilotumumab or ganitumab plus chemotherapy as first-line treatment in small-cell lung cancer. Patients received rilotumumab or ganitumab plus chemotherapy (phase 1b, n=28), or were randomized to receive placebo, rilotumumab, or ganitumab plus chemotherapy (phase 2, n=185). One patient treated with ganitumab experienced a dose-limiting toxicity. No significant differences in outcomes were observed between treatments.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2q49u20
via IFTTT